Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rifampin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 3/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 2/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 2/20 | 1.00 |
| ▸ | ABCC2 | Q92887 | 2/20 | 1.00 |
| ▸ | SLCO2B1 | O94956 | 2/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 2/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | SLCO1A2 | P46721 | 2/20 | 1.00 |
| ▸ | SLCO1B3 | Q9NPD5 | 2/20 | 1.00 |
| ▸ | SLCO1B1 | Q9Y6L6 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rifampin SCHEMBL14029509 | 1.00 | MAPT (1.00) | MAPTNR1I2ABCB11ALDH1A1KDM4E | |
| Rifampin SCHEMBL13230041 | 1.00 | MAPT (1.00) | MAPTNR1I2ABCB11ALDH1A1KDM4E | |
| Rifampin SCHEMBL14922822 | 1.00 | MAPT (1.00) | MAPTNR1I2ABCB11ALDH1A1KDM4E | |
| Rifampin SCHEMBL14252040 | 1.00 | MAPT (1.00) | MAPTNR1I2ABCB11ALDH1A1KDM4E | |
| Rifampin SCHEMBL14927261 | 1.00 | MAPT (1.00) | MAPTNR1I2ABCB11ALDH1A1KDM4E | |
| Rifampin SCHEMBL16499164 | 1.00 | MAPT (1.00) | MAPTNR1I2ABCB11ALDH1A1KDM4E | |
| Rifampin SCHEMBL66289 | 1.00 | MAPT (1.00) | MAPTNR1I2ABCB11ALDH1A1KDM4E | |
| Rifampin SCHEMBL15472876 | 1.00 | MAPT (1.00) | MAPTNR1I2ABCB11ALDH1A1KDM4E | |
| Rifampin SCHEMBL22432205 | 1.00 | MAPT (1.00) | MAPTNR1I2ABCB11ALDH1A1KDM4E | |
| Rifampin SCHEMBL19457678 | 1.00 | MAPT (1.00) | MAPTNR1I2ABCB11ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1050 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122031717-A | Efficient stable high-biocompatibility nano delivery carrier and preparation method and application thereof | 广州墨羲科技有限公司 | 2026-05-15 | — | — | CN | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| US-20260108455-A1 | DEVICE FOR SUSTAINED CONTROLLED RELEASE OF A THERAPEUTICALLY ACTIVE SUBSTANCE AND USES THEREOF | HYLOMORPH AG (CH) | 2026-04-23 | — | — | US | claimed |
| EP-3790536-B1 | NANOCONTAINERS FOR TRANSPORTING NONPOLAR, LIPOPHILIC SUBSTANCES SUCH AS ANTIBIOTICS | KARLSRUHER INST TECHNOLOGIE (DE) | 2026-04-22 | — | — | EP | claimed |
| US-20260091127-A1 | JANUS PARTICLE-EMBEDDED MATERIALS FOR ANTIMICROBIAL APPLICATIONS | UNIV INDIANA TRUSTEES (US) | 2026-04-02 | — | — | US | claimed |
| EP-4554557-B1 | DEVICE FOR SUSTAINED CONTROLLED RELEASE OF A THERAPEUTICALLY ACTIVE SUBSTANCE AND USES THEREOF | HYLOMORPH AG (CH) | 2026-03-11 | — | — | EP | claimed |
| EP-4042999-B1 | DRUG ACCOMMODATING DEVICE OF SOLID ORAL FORMULATION, AND ORAL ADMINISTRATION AND DELIVERY APPARATUS COMPRISING SAME | SHANGHAI WD PHARMACEUTICAL CO LTD (CN) | 2026-03-04 | — | — | EP | claimed |
| EP-4121058-B1 | OXAZOLIDINONE COMPOUND AND ITS USE THEREOF AS AN ANTIBACTERIAL AGENT | MERCK SHARP & DOHME LLC (US) | 2026-02-18 | — | — | EP | claimed |
| EP-4076461-B1 | LUMATEPERONE FOR USE IN SCHIZOPHRENIA TREATMENT | INTRA CELLULAR THERAPIES INC (US) | 2026-01-28 | — | — | EP | claimed |
| EP-4363415-B1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | TECNIMEDE SOCIEDADE TECNICO MEDICINAL SA (PT) | 2025-12-10 | — | — | EP | claimed |
| EP-3618813-B1 | IMPROVED EXTENDED RELEASE HIGHLY LOADED DRUG COMPOSITIONS | LUBRIZOL ADVANCED MAT INC (US) | 2022-07-06 | — | — | EP | claimed |
| EP-3265083-B1 | SUBSTITUTED UREA DEPSIPEPTIDE ANALOGS AS ACTIVATORS OF THE CLPP ENDOPEPTIDASE | ST JUDE CHILDRENS RES HOSPITAL (US) | 2022-07-06 | — | — | EP | claimed |
| EP-2999711-B1 | POLYMYXIN DERIVATIVES AND THEIR USE IN COMBINATION THERAPY TOGETHER WITH DIFFERENT ANTIBIOTICS | SPERO THERAPEUTICS INC (US) | 2022-06-29 | — | — | EP | claimed |
| CN-108949949-B | Drug transport protein gene polymorphism site related to anti-tubercular drug hepatic injury and application thereof | 上海市预防医学研究院 | 2022-06-28 | — | — | CN | claimed |
| CN-108949947-B | Cytochrome P450 gene polymorphic site related to generation of anti-tubercular drug liver injury | 上海市预防医学研究院 | 2022-06-28 | — | — | CN | claimed |
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| US-11308612-B2 | Systems and methods for detection of infectious respiratory diseases | QURE.AI TECHNOLOGIES PRIVATE LIMITED (IN) | 2022-04-19 | — | — | US | claimed |
| EP-3500254-B1 | PHARMACEUTICAL COMPOSITION CONTAINING POLYMYXIN B/TRIMETHOPRIM BASED THERAPEUTICS | UNIV ROCHESTER (US) | 2022-03-23 | — | — | EP | claimed |
| US-11241427-B2 | Small molecule modulators of NR2F6 activity | KCL THERAPEUTICS, INC. (US) | 2022-02-08 | — | — | US | claimed |
| EP-3941206-A1 | NEW USES OF A MUTATED LACTONASE, AND COMPOSITIONS | Fondation Méditerranée Infection (FR) | 2022-01-26 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091127-A1 | JANUS PARTICLE-EMBEDDED MATERIALS FOR ANTIMICROBIAL APPLICATIONS | MKI67, PIM1, ABCC1 | MAPT 822/4885NR1I2 2019/4885ABCB11 645/4885 |
| US-11241427-B2 | Small molecule modulators of NR2F6 activity | NR2F2, NR2E3, NR2C2 | MAPT 4811/4885NR1I2 564/4885ABCB11 4628/4885 |
| US-20260108455-A1 | DEVICE FOR SUSTAINED CONTROLLED RELEASE OF A THERAPEUTICALLY ACTIVE SUBSTANCE AND USES THEREOF | PGF, VEGFA, LDHB | MAPT 3307/4885NR1I2 2139/4885ABCB11 1515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.